And what’s behind these shifts, according to JLL’s latest research.
Calling the life science sector’s start to this year “disquieting,” a just-released report from JLL examines the multiple uncertainties that are making investors and pharma companies cautious and leasing deals smaller on average.
One measure of this is that the U.S. lab market, which totals roughly 200 million square feet, would need about 20 million to 25 million in net absorption or supply reduction to reach equilibrium, according to JLL’s latest study.
“Barring an unforeseen and substantial growth spurt of demand,” JLL writes, “the likeliest outcome of this period of oversupply is that well-built and well-located buildings will gain market share, while buildings without those aspects will face increased odds of distress in the next 12-24 months.”...
...more
RSK: I have faith in the life sciences sector and am sure it will rebound especially in our market area.
Share this article on you social outlets
Our Sponsors
- - Volume: 25 - WEEK: 26 Date: 6/24/2025 10:16:54 AM -